npj Genomic Medicine (Mar 2022)

VHL mosaicism: the added value of multi-tissue analysis

  • Leslie E. Oldfield,
  • Jessica Grzybowski,
  • Sylvie Grenier,
  • Elizabeth Chao,
  • Gregory S. Downs,
  • Kirsten M. Farncombe,
  • Tracy L. Stockley,
  • Ozgur Mete,
  • Raymond H. Kim

DOI
https://doi.org/10.1038/s41525-022-00291-3
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Von Hippel-Lindau disease (VHL) is an autosomal dominant, inherited syndrome with variants in the VHL gene causing predisposition to multi-organ benign and malignant neoplasms. A germline VHL variant is identified in 95–100% of individuals with a clinical diagnosis of VHL. Here, we present the case of an individual with a clinical diagnosis of VHL disease where peripheral blood DNA analysis did not detect a VHL variant. Sequencing of four tumor tissues (ccRCC, pheochromocytoma, lung via sputum, liver) revealed a VHL c.593 T > C (p.Leu198Pro) variant at varying allele fractions (range: 10–55%) in all tissues. Re-examination of the peripheral blood sequencing data identified this variant at 6% allele fraction. Tumor analysis revealed characteristic cytomorphological, immunohistochemical reactivity for alpha-inhibin, and CAIX, and reduced pVHL reactivity supported VHL-related pseudohypoxia. This report of a rare case of VHL mosaicism highlights the value of tissue testing in VHL variant negative cases.